- Home
- FA vs IMCR Comparison
FA vs IMCR Comparison
Compare FA & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FA | IMCR |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FA | IMCR |
|---|---|---|
| Price | $12.10 | $33.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $15.50 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 1.5M | 379.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,574,389,000.00 | $249,428,000.00 |
| Revenue This Year | $8.11 | $14.39 |
| Revenue Next Year | $7.34 | $8.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 83.02 | 43.05 |
| 52 Week Low | $8.82 | $23.15 |
| 52 Week High | $19.01 | $40.71 |
Technical Indicators
Market Signals| Indicator | FA | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 50.92 |
| Support Level | $8.82 | $31.21 |
| Resistance Level | $14.56 | $34.86 |
| Average True Range (ATR) | 0.65 | 1.72 |
| MACD | 0.40 | 0.10 |
| Stochastic Oscillator | 82.45 | 57.18 |
Price Performance
Historical ComparisonAbout FA First Advantage Corporation
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.